Cargando…

Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications

Pancreatic tumor microenvironment (TME) is characterized by poor tumor-vasculature and extensive desmoplasia that together contribute to poor response to chemotherapy. It was recently shown that targeting of TME to inhibit desmoplasiatic reaction in a preclinical model resulted in increased microves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Mohammad Aslam, Srivastava, Sanjeev K., Bhardwaj, Arun, Singh, Seema, Arora, Sumit, Zubair, Haseeb, Carter, James E., Singh, Ajay P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770762/ https://www.ncbi.nlm.nih.gov/pubmed/25970774

Ejemplares similares

Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
por: Patel, Girijesh Kumar, et al.
Publicado: (2017)

Honokiol Arrests Cell Cycle, Induces Apoptosis, and Potentiates the Cytotoxic Effect of Gemcitabine in Human Pancreatic Cancer Cells
por: Arora, Sumit, et al.
Publicado: (2011)

Deep sequencing and in silico analyses identify MYB-regulated gene networks and signaling pathways in pancreatic cancer
por: Azim, Shafquat, et al.
Publicado: (2016)

Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages
por: Deshmukh, Sachin Kumar, et al.
Publicado: (2018)

Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy
por: Arora, Sumit, et al.
Publicado: (2014)

MYB is a novel regulator of pancreatic tumour growth and metastasis
por: Srivastava, Sanjeev K, et al.
Publicado: (2015)

Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward
por: Khan, Mohammad Aslam, et al.
Publicado: (2017)

Resistin Induces LIN28A-Mediated Let-7a Repression in Breast Cancer Cells Leading to IL-6 and STAT3 Upregulation
por: Deshmukh, Sachin Kumar, et al.
Publicado: (2021)

Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer
por: Acharya, Srijan, et al.
Publicado: (2022)

MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and -independent pathways
por: Srivastava, Sanjeev K, et al.
Publicado: (2015)

Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications
por: Patel, Girijesh Kumar, et al.
Publicado: (2019)

Development and Characterization of a Novel in vitro Progression Model for UVB-Induced Skin Carcinogenesis
por: Tyagi, Nikhil, et al.
Publicado: (2015)

CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1
por: Bhardwaj, Arun, et al.
Publicado: (2014)

Modulation of MicroRNAs by Phytochemicals in Cancer: Underlying Mechanisms and Translational Significance
por: Srivastava, Sanjeev K., et al.
Publicado: (2015)

p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling
por: Tyagi, Nikhil, et al.
Publicado: (2015)

Cancer Chemoprevention by Phytochemicals: Nature’s Healing Touch
por: Zubair, Haseeb, et al.
Publicado: (2017)

CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
por: Singh, S, et al.
Publicado: (2010)

p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway
por: Tyagi, Nikhil, et al.
Publicado: (2014)

Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis
por: Srivastava, S K, et al.
Publicado: (2015)

Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation
por: Deshmukh, Sachin K., et al.
Publicado: (2015)

Exosomal Formulation Escalates Cellular Uptake of Honokiol Leading to the Enhancement of Its Antitumor Efficacy
por: Kanchanapally, Rajashekhar, et al.
Publicado: (2020)

Comprehensive Analysis of Expression, Clinicopathological Association and Potential Prognostic Significance of RABs in Pancreatic Cancer
por: Anand, Shashi, et al.
Publicado: (2020)

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
por: Kondo, Shunsuke, et al.
Publicado: (2012)

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
por: Friess, Helmut, et al.
Publicado: (2006)

Size is an essential parameter in governing the UVB-protective efficacy of silver nanoparticles in human keratinocytes
por: Palanki, Rohan, et al.
Publicado: (2015)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Detection of mitochondrial DNA mutations in circulating mitochondria-originated extracellular vesicles for potential diagnostic applications in pancreatic adenocarcinoma
por: Vikramdeo, Kunwar Somesh, et al.
Publicado: (2022)

Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
por: Saranyutanon, Sirin, et al.
Publicado: (2019)

Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism
por: Donadelli, M, et al.
Publicado: (2011)

Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer
por: Park, Ji Min, et al.
Publicado: (2022)

Extracellular Nanovesicles: From Intercellular Messengers to Efficient Drug Delivery Systems
por: Deshmukh, Sachin Kumar, et al.
Publicado: (2021)

ETV4: an emerging target in pancreatic cancer
por: Deshmukh, Sachin Kumar, et al.
Publicado: (2018)

Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
por: Habib, Saffiya, et al.
Publicado: (2021)

Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer
por: Miree, Orlandric, et al.
Publicado: (2021)

EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic Cancer
por: Tang, Su-Ni, et al.
Publicado: (2012)

The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas
por: Beyer, Sasha, et al.
Publicado: (2017)

VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo
por: Kang, Guangbo, et al.
Publicado: (2021)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_em7q3uo5reibbcrlvo19g8hc42